Should C-reactive protein be measured routinely during acute myocardial infarction?

American Journal of Medicine

Volumn 115, Issue 9, 2003, Pages 735-737

  Zebrack, James S ^a,b   Anderson, Jeffrey L ^b,c  

^a Heart Center   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c LDS Church   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PROBUCOL;

ACUTE HEART INFARCTION; ANGIOGENESIS; CARDIOVASCULAR RISK; CORONARY ARTERY LIGATION; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; ERYTHROCYTE AGGREGATION; EXPERIMENTAL RAT; GLUCOSE TOLERANCE; GROWTH INHIBITION; HEART VENTRICLE THROMBOSIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK FACTOR; TREATMENT INDICATION;

EID: 0348048831     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.10.006     Document Type: Editorial

References (20)

1. Spertus J.A., Radford M.J., Every N.R., et al. Challenges and opportunities in quantifying the quality of care for acute myocardial infarction summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke . J Am Coll Cardiol. 41:2003;1653-1663.
2. Pearson T.A., Mensah G., Alexander W., et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association . Circulation. 107:2003;499-511.
3. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide . Circulation. 105:2002;1760-1763.
4. Zebrack J.S., Muhlestein J.B., Horne B.D., et al. C-reactive protein and angiographic coronary artery disease independent and additive predictors of risk in subjects with angina . J Am Coll Cardiol. 39:2002;632-637.
5. Kushner I., Broder M.L., Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 61:1978;235-242.
6. Zebrack J.S., Anderson J.L., Maycock C.A., et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 89:2002;145-149.
7. Tommasi S., Carluccio E., Bentivoglio M., et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol. 83:1999;1595-1599.
8. Anzai T., Yoshikawa T., Shiraki H., et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 96:1997;778-784.
9. Pietila K.O., Harmoinen A.P., Jokiniitty J., et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 17:1996;1345-1349.
10. Berton G., Cordiano R., Palmieri R., et al. C-reactive protein in acute myocardial infarction association with heart failure . Am Heart J. 145:2003;1094-1101.
11. Kinjo K., Sato H., Ohnishi Y., et al. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol. 91:2003;931-935.
12. Suleiman M., Aronson D., Reisner S.A., et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med. 115:2003;695-701.
13. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 190:1999;1733-1740.
14. Widmer A., Linka A.Z., Attenhofer Jost C.H., et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 99:2003;25-31.
15. Nijmeijer R., Lagrand W.K., Lubbers Y.T., et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol. 163:2003;269-275.
16. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy C-reactive protein attenuates nitric oxide production and inhibits angiogenesis . Circulation. 106:2002;913-919.
17. Fusman G., Mardi T., Justo D., et al. Red blood cell adhesiveness/ aggregation, C-reactive protein, fibrinogen, and erythrocyte sedimentation rate in healthy adults and in those with atherosclerotic risk factors. Am J Cardiol. 90:2002;561-563.
18. Celik S., Baykan M., Erdol C., et al. C-reactive protein as a risk factor for left ventricular thrombus in patients with acute myocardial infarction. Clin Cardiol. 24:2001;615-619.
19. Uehara K., Nomura M., Ozaki Y., et al. High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels. 18:2003;67-74.
20. Anzai T., Yoshikawa T., Takahashi T., et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology. 99:2003;47-53.